Schwartz P E, Keating G, Kohorn E I, Chambers J T
Gynecol Oncol. 1986 Nov;25(3):340-6. doi: 10.1016/0090-8258(86)90085-5.
Nineteen patients with stage III or IV epithelial ovarian cancer treated on a prospective randomized protocol with either adriamycin and cis-diamminedichloroplatinum or tamoxifen, adriamycin, and cis-diamminedichloroplatinum received a modified "CHAP II" regimen at the time of clinical progression of disease or the finding of occult cancer at second-look surgery. One patient had a clinical complete response lasting 6 months, one had a partial response lasting 23 months, 6 had clinically stable disease for an average of 6.5 months (range 4-15 months), 8 patients had progressive disease, and 3 patients without clinically detectable disease remained disease free for a mean time of 10 months (range 7-16 months). The modified "CHAP II" regimen employed in this study for patients failing prior cis-diamminedichloroplatinum-based regimens appears to have only limited efficacy in inducing objective remissions.
19例III期或IV期上皮性卵巢癌患者，按照前瞻性随机方案，接受阿霉素和顺二氨二氯铂治疗，或他莫昔芬、阿霉素和顺二氨二氯铂治疗。在疾病临床进展或二次探查手术发现隐匿性癌时，这些患者接受了改良的“CHAP II”方案治疗。1例患者出现持续6个月的临床完全缓解，1例出现持续23个月的部分缓解，6例患者临床病情稳定，平均持续6.5个月（范围4 - 15个月），8例患者病情进展，3例无临床可检测到疾病的患者无病生存平均时间为10个月（范围7 - 16个月）。本研究中用于先前基于顺二氨二氯铂方案治疗失败患者的改良“CHAP II”方案，在诱导客观缓解方面似乎仅有有限的疗效。
